Authors

Latest:

Dr. Butler on the Importance of Health Literacy Initiatives

Thomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.

Thomas C. Krivak, MD

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Thomas D. Coates, MD

Thomas D. Coates, MD, University of Southern California Keck School of Medicine

Thomas E. Hutson, DO, Pharm.D., FACP

Latest:

An Individualized Approach to Treating Advanced RCC

Grounded in a collaborative and personalized approach, researcher and clinician Dr. Thomas Hutson expands on his best practices for treating certain people living with advanced RCC with a combination therapy.

Thomas E. Hutson, DO, PharmD, Baylor University Medical Center

Thomas E. Hutson, DO, PharmD, Texas Oncology

Latest:

Series Wrap-up: Novel Therapies for mRCC

A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.

Thomas E. Stinchcombe, MD

Latest:

Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLC

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, Duke Cancer Center

Thomas E. Stinchcombe, MD, Duke Cancer Institute

Thomas E. Stinchcombe, MD, Duke University Health System

Thomas E. Stinchcombe, MD, UNC

Thomas E. Stinchcombe, MD, University of North Carolina at Chapel Hill

Thomas E. Witzig, MD

Latest:

Dr. Witzig on Emerging Agents in Diffuse Large B-Cell Lymphoma

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the emerging agents being utilized in the treatment of patients with diffuse large B-cell lymphoma.

Thomas F. Gajewski, MD, PhD

Latest:

Dr Gajewski on the Role of the Gut Microbiome in Immunotherapy Response Regulation

Thomas F. Gajewski, MD, PhD, discusses the mechanism through which the gut microbiome modulates myeloid cells to regulate responses to immunotherapy.

Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Dr. Martin on the Patient Population of the CARTITUDE-1 Study in R/R Multiple Myeloma

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Thomas G. Martin, MD, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Thomas Helleday, PhD

Latest:

Similarity of Biosimilars and Biologics

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

Thomas J. Herzog, MD

Latest:

Adverse Event Management and Emerging Therapies in Ovarian Cancer: PARPi Challenges and the Role of ADCs

Panelists discuss the most common adverse events associated with PARP inhibitor (PARPi) therapy in ovarian cancer and strategies for mitigating or managing these adverse effects. They also review recent data on antibody-drug conjugates (ADCs) in ovarian cancer, including the evolving role of mirvetuximab soravtansine in the FORWARD II trial, and other ADCs such as luveltamab tazevibulin and rinatabart sesutecan, highlighting promising findings from studies presented at ESMO 2024. The session concludes with a discussion on future perspectives in ovarian cancer treatment, offering insights into emerging therapies and the evolving landscape.